Fig. 8
Treatment with erlotinib inhibits tumor growth but fails to alleviate cisplatin-induced cancer cachexia in MBT-2 bladder tumor-bearing mice. a Treatment schedule. Groups of male C3H/HeN mice were subcutaneously inoculated with 3 × 106 of MBT-2 cells at day 0. The mice were intraperitoneally treated with erlotinib (10 mg/kg/day) daily from day 15 to day 21 in combination with cisplatin (5 mg/kg/day) at days 15, 17, 19, and 21 and sacrificed at day 23. b Body weight (after subtraction of the estimated tumor weight, which was estimated as 1 mm3 tumor volume equal to 1 mg) was expressed as a percentage of the body weight at day 0. c Calf circumference was measured at day 23 before sacrifice. d Tumor volumes were measured every 2 or 3 days. Values shown are mean ± SD (n = 6)